Stem Cell Therapy in Stargardt Disease: A Systematic Review.
Atousa Moghadam FardReza MirshahiMasood NaseripourKhalil Ghasemi FalavarjaniPublished in: Journal of ophthalmic & vision research (2023)
This article aimed to review current literature on the safety and efficacy of stem cell therapy in Stargardt disease. A comprehensive literature search was performed, and two animal and eleven human clinical trials were retrieved. These studies utilized different kinds of stem cells, including human or mouse embryonic stem cells, mesenchymal stem cells, bone marrow mononuclear fraction, and autologous bone marrow-derived stem cells. In addition, different injection techniques including subretinal, intravitreal, and suprachoroidal space injections have been evaluated. Although stem cell therapy holds promise in improving visual function in patients with Stargardt disease, further investigation is needed to determine the long-term benefits, safety, and efficacy in determining the best delivery method and selecting the most appropriate stem cell type.
Keyphrases
- cell therapy
- stem cells
- mesenchymal stem cells
- bone marrow
- endothelial cells
- clinical trial
- umbilical cord
- systematic review
- embryonic stem cells
- induced pluripotent stem cells
- machine learning
- randomized controlled trial
- diabetic retinopathy
- peripheral blood
- optical coherence tomography
- platelet rich plasma
- phase ii
- smoking cessation